Новости Geistlich Pharma AG

Prof. Dr. Frauke Müller pushes the door to geriatric dentistry wide open. She introduces listeners to her fascinating and multifaceted field, which has many special features compared to general dentistry. The specialist from the University of Geneva is a guest on the new Geistlich Audio Podcast.

Let's look back: The "Geistlich Charity Walk & Run" moved the hearts of 352 employees. In September 2021, they ran and walked the race, covering a total of 4,191 kilometers. This resulted in a donation of 20,955 US dollars, which has now reached its destination.

Since 26 May 2021, the new and stricter legislation for the market authorization of medical devices in the EU, the Medical Device Regulation (MDR), has been in force. Geistlich Pharma obtained the first MDR certificates in August 2021, both for the quality management system and for the first product family, Geistlich Fibro-Gide^®. This paves the way for continued market access of all Geistlich Pharma products in the EU. Nicole Guetg, Senior Regulatory Affairs Manager, and Reinhart Seibl, Director Regulatory Affairs, discuss the background.

In the festive setting of the event organised by the Chamber of Industry and Commerce of Central Switzerland (ihz), Geistlich CEO Ralf P. Halbach and his team accept the Innovation Recognition Award for Geistlich Derma-Gide^®.

Geistlich Pharma has been working successfully with Meta, the medical technology division of C.G.M. S.p.A., for many years. With the acquisition of Meta Technologies S.r.l., Geistlich Pharma is expanding its existing offering as a regeneration specialist by adding a further recognized brand. Meta Technologies S.r.l. will continue its business relationships independently

Geistlich Pharma obtains 510(k) clearance from the US Food and Drug Administration (FDA) for its latest product Geistlich Nexo-Gide^®. It will be presented at surgical podiatry and orthopaedic congresses in Florida and Nevada from November 2021. For patients with severe tendon and ligament injuries, the collagen membrane increases the likelihood of successful surgical procedures.

Geistlich Pharma wins the Innovation Recognition Award for the medical device Geistlich Derma-Gide^®. Launched on the US market in 2019, the product particularly supports the healing process of foot ulcers that occur as a late consequence of diabetes. The novel wound matrix is an innovation that was developed 100% in Central Switzerland, is produced here.

Five questions for Friedrich Buck, who is responsible for Geistlich's "Scientific Education" with his team. He himself is a dentist with many years of experience. What current topics are driving him and what dental education offers should you be aware of following the pandemic?

Geistlich Pharma's Surgery business unit becomes the exclusive distribution partner for the NUsurface^® meniscus implant in Switzerland and enters into an exclusive partnership with Active Implants. The objective of both companies is to support pain patients by preserving joints.

Last weekend Geistlich once again called for the "Geistlich Charity Walk & Run". The employees came in droves: Participants around the world ran for a donation of 20,955 US dollars. This will benefit a children's dental project in China.